Doctorate Tianyao Wang: Assistant Researcher at Peking University First Hospital, China
Dr. Tianyao (Tim) Wang is an Assistant Researcher at the Department of Nuclear Medicine, Peking University First Hospital. He received his Ph.D. in Nuclear Engineering from Texas A&M University, where he also completed a Certificate in Business from Mays Business School. His research spans radiopharmaceutical development, PET molecular imaging, accelerator-based isotope production, and radiation-material interactions. Dr. Wang has authored 33 high-impact publications, holds multiple invention patents, and serves as PI or co-PI on over ten national and international research grants. As of 2025, he has accumulated 613 citations with an h-index of 12 and an i10-index of 16.
Online Profiles
Google Scholar: Tianyao Wang – Google Scholar
Education
Dr. Wang completed his Ph.D. in Nuclear Engineering at Texas A&M University (2015–2020) with a 3.8 GPA, where his dissertation focused on the radiation responses of bulk metallic glasses. He also earned a Certificate in Business from Mays Business School during his Ph.D. studies. He received his B.S. in Nuclear Science and Technology from Harbin Engineering University (2011–2015), graduating with a 3.7 GPA and being awarded the Best Undergraduate Award (1st out of 3,300 students) along with three consecutive National Scholarships.
Research Focus
Dr. Wang’s research integrates nuclear engineering, clinical molecular imaging, and material science. His current interests include the development of novel PET radiotracers targeting cancer-related biomarkers (e.g., CD38, BCMA, c-Met), dual-target immunoPET probes, and clinical translation of nanobody-based diagnostic agents. He also explores ion beam modification, helium interaction with structural materials, and the operation of cyclotron and accelerator systems for isotope production.
Experience
Dr. Wang is currently leading several translational radiopharmaceutical imaging projects at Peking University First Hospital. Prior to this, he was Project Leader at Zhejiang University/Boomy United Lab, where he developed GMP radiopharmacy systems and advanced business planning for the nuclear sector. He also worked as a management consultant at ByteDance, focusing on strategic business structuring for metaverse and public cloud divisions. His foundational research experience was shaped by NSF-funded graduate and internship work at Texas A&M University and Argonne National Laboratory.
Research Timeline
-
2023–Present: Assistant Researcher, Peking University First Hospital (Nuclear Medicine)
-
2022–2023: Project Leader, Zhejiang University/Boomy United Lab
-
2021–2022: Management Consultant, ByteDance/TikTok Ltd. (Beijing)
-
2015–2020: Graduate Research Assistant, Texas A&M University / NSF Projects
-
2016 (Fall): Ph.D. Research Intern, Argonne National Laboratory (USA)
Awards & Honors
Dr. Wang has received prestigious recognitions including the Best Undergraduate Award (Harbin Engineering University), three-time National Scholarship (Top 1% in China), and funding awards from the NSFC, China Postdoctoral Foundation, and multiple Peking University research initiatives. His PI-led grants total over RMB 700,000, while he has contributed as a core team member to additional projects exceeding RMB 3 million and USD 1 million in total funding.
Top-Noted Publication
A notable highlight of Dr. Wang’s work is his 2025 publication in European Journal of Nuclear Medicine and Molecular Imaging titled: “ImmunoPET imaging of c-Met using a nanobody-based tracer [68Ga]Ga-NOTA-PFCM01 in pancreatic ductal adenocarcinoma models and non-human primates”. This study exemplifies his contributions to precision oncology, showcasing successful translational imaging from animal models to potential human clinical applications.
-
CD38-specific immunoPET imaging for multiple myeloma diagnosis and therapeutic monitoring: preclinical and first-in-human studies
W. Huang, T. Wang, Y. Qiu, et al.
European Journal of Nuclear Medicine and Molecular Imaging, 2025, 10 citations
[DOI: 10.1007/s00259-024-07036-7]
Clinical translation of a novel CD38-targeted PET tracer for multiple myeloma. -
The effect of internal free surfaces on void swelling of irradiated pure iron containing subsurface trenches
T. Wang, H. Kim, F.A. Garner, K.L. Peddicord, L. Shao
Crystals, 2019, 8 citations
[DOI: 10.3390/cryst9050252]
Study of radiation damage and defect evolution in iron structures. -
Influence of topological constraints on ion damage resistance of amorphous hydrogenated silicon carbide
Q. Su, T. Wang, J. Gigax, et al.
Acta Materialia, 2019, 6 citations
[DOI: 10.1016/j.actamat.2018.12.016]
Insights into radiation tolerance in amorphous semiconductors. -
Development of a Novel Peptide-Based PET Tracer [68Ga]Ga-DOTA-BP1 for BCMA Detection in Multiple Myeloma
L. Song, S. Jiang, Q. Yang, T. Wang, et al.
Journal of Medicinal Chemistry, 2024, 5 citations
[DOI: 10.1021/acs.jmedchem.4c00759]
First-in-class BCMA-targeted peptide PET tracer for MM detection. -
Enhanced Theranostic Efficacy of 89Zr and 177Lu-Labeled Aflibercept in Renal Cancer: A Viable Option for Clinical Practice
Z. Chen, Q. Yang, L. Song, T. Wang, et al.
Molecular Pharmaceutics, 2024, 4 citations
[DOI: 10.1021/acs.molpharmaceut.4c00084]
Dual-labeled aflibercept for imaging and therapy of renal cancer.